Is the price fair?
What FTRE's price assumes
Fortrea Holdings Inc. did not earn a profit over the last twelve months, so it has no trailing P/E and the price is read against sales instead: 0.33× revenue.
0.33
Price / sales · no P/E: the last twelve months did not end in a profit
- Free cash flow yield
- 13%
Free cash flow yield · Biotechnology median 2.5%
- Growth the price implies
- −7.4%
Growth the price implies · The price pays for −7.4% free cash flow growth a year for a decade; revenue has grown −0.53% a year over the last three.
- Price / book
- 1.68
Price / book · as of 2026-Q1
Details›
- Price / book2026-Q1
- 1.68
- EV / EBIToperating margin −13%: the multiple describes the denominator
- not meaningful
- EV / sales2026-Q1
- 0.66
- Free cash flow, trailing twelve months
- $190M
- Market capitalisation
- $1.45B
- 3-year revenue growth
- −0.53%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.